A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Name: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Published: 2022
License: Public Domain

Eli Lilly and Company · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

alzheimer-disease alzheimer-s cognitive-impairment dementia mental-disorders neurodegenerative-diseases

alzheimer disease, dementia, brain diseases, central nervous system diseases, nervous system diseases, tauopathies, neurodegenerative diseases, neurocognitive disorders, mental disorders, alzheimer's, cognitive impairment, amyloid plaque

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 915328
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.